Infusion of CD30 CAR T-cells following AuHCT in patients with lymphoma

CD30-Specific CAR T Cells in Patients With Relapsed/Refractory Hodgkin LymphomaПодробнее

Understanding CAR T-cell Therapy in LymphomaПодробнее

Dual-targeting CD30/PDL1 CAR-T therapy in Hodgkin lymphomaПодробнее

CD30-directed CAR-Ts co-expressing CCR4 in R/R HL and CD30+ CTCLПодробнее

Can CD30 CAR T-cell consolidation improve outcomes after ASCT for patients with CD30+ lymphomas?Подробнее

CD30, a promising target for CAR-T therapy in Hodgkin lymphomaПодробнее

The Potential of CD30 CAR T Cell Therapy for the Treatment of CD30-Positive LymphomasПодробнее

CAR T-cell Therapy: A game changer for #cancertreatment #immunotherapy #cancerПодробнее

‘Off-the-shelf’ EBV-specific CAR-T cells for Hodgkin lymphomaПодробнее

CAR T-cell Therapy VideoПодробнее

CAR T-cells in lymphoma: new advances and practical aspectsПодробнее

The role of cellular immunotherapies in the future treatment of HLПодробнее

CAR-T cell therapy in lymphomaПодробнее

Carlos Ramos | ASH 2018 | CD30 CAR-T therapy for HLПодробнее

Why should we use CAR30 memory T cells to treat Hodgkin and T-cell lymphoma?Подробнее

CAR-T in LymphomaПодробнее

When is a second CAR T-cell infusion feasible for patients who failed prior CAR T-cell therapy?Подробнее

CAR T-cell in lymphomaПодробнее

Phase 1 trial of CAR T-cell therapy for lymphomaПодробнее